China Health Group Limited (stock code: 673) has announced an agreement to allot and issue 48 million new shares at HK$0.53 each under a general mandate. The new shares represent approximately 3.58% of the current issued share capital and about 3.46% of the enlarged share capital upon completion. According to the announcement dated 2 February 2026, the company and the subscriber, a Hong Kong-based investment holding entity wholly owned by Zhang Xiaoling, reached the agreement after trading hours on that date.

The subscription price reflects a discount of around 13.11% to the closing price of HK$0.61 on the last trading day and an approximately 18.46% discount to the five-day average of HK$0.65. The transaction is set to raise gross proceeds of about HK$25.44 million, with estimated net proceeds of HK$25.27 million. Of the net proceeds, HK$10 million (around 40%) are earmarked for future investments, while HK$15.27 million (around 60%) will be used as general working capital of the group, including daily operating expenses and payables.

Completion of the subscription is subject to conditions including approval by the Listing Committee of The Stock Exchange of Hong Kong Limited for the listing of and permission to deal in the new shares. The subscriber has agreed to a 6-month lock-up period following completion. If all conditions are fulfilled, the transaction is expected to be completed on the 10th business day thereafter or on another agreed date. The announcement indicates that shareholders and potential investors should exercise caution when dealing in the company’s shares, as the subscription may or may not proceed.